| 产品描述： | 选择性变构FGFR抑制剂。高效的抗增殖剂。;Selective allosteric FGFR inhibitor. Potent antiproliferative agent.;产品介绍：SSR128129E是口服效果较好的变构FGFR抑制剂，IC50为1.9μM，对别的关联RTKs无效果。; |
| 体内研究： |
Oral delivery of SSR128129E (30 mg/kg/day, from day 3) inhibits growth of orthotopic Panc02 tumors by 44% and delays growth of Lewis lung carcinoma. oral SSR128129E (30 mg/kg/day, from day 5) reduces tumor size and weight by 53% and 40%, respectively. SSR128129E inhibits the growth of subcutaneous CT26 colon tumors by 34% and of the multidrug resistant MCF7/ADR breast cancer xenograft model by 40%. SSR128129E reduces tumor invasiveness and metastasis of Panc02 tumor cells to peritoneal lymph nodes. |
| 参考文献： |
1. Bono F, et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell. 2013 Apr 15;23(4):477-88. |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.888 ml |
14.438 ml |
28.876 ml |
| 5 mM |
0.578 ml |
2.888 ml |
5.775 ml |
| 10 mM |
0.289 ml |
1.444 ml |
2.888 ml |
| 50 mM |
0.058 ml |
0.289 ml |
0.578 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京